To rigorously investigate whether KRAS mutations confer platinum resistance in lung cancer cells, we adopted 2 approaches: overexpressing a constitutively active KRAS mutant in NCI-H522 (KRAS WT) and knocking down KRAS in NCI-H23 (KRAS G12C) cells. This evidence concerns the gene KRAS and lung carcinoma.